Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 7/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 5/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907490 | 0.92 | UGCG (0.75) | UGCGMAPTTHRBSMN1; SMN2TP53 | |
| SCHEMBL29907628 | 0.87 | UGCG (0.61) | UGCGMAPTTHRBSMN1; SMN2TP53 | |
| SCHEMBL29907503 | 0.85 | UGCG (0.60) | UGCGMAPTTHRBSMN1; SMN2TP53 | |
| SCHEMBL29907410 | 0.83 | UGCG (0.75) | UGCGMAPTTHRBSMN1; SMN2 | |
| SCHEMBL29907407 | 0.80 | UGCG (0.61) | UGCGMAPTTHRBSMN1; SMN2RXFP1 | |
| SCHEMBL29907426 | 0.78 | UGCG (1.00) | UGCGMAPTLCLAT1 | |
| SCHEMBL29907465 | 0.76 | UGCG (0.52) | UGCGDHODHTRPV1LCLAT1 | |
| SCHEMBL29907497 | 0.75 | UGCG (0.81) | UGCGTRPV1 | |
| SCHEMBL29907428 | 0.75 | UGCG (0.60) | UGCG | |
| SCHEMBL29907592 | 0.73 | UGCG (1.00) | UGCGMAPTSMN1; SMN2CYP2C9RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | UGCG 10/4885MAPT 772/4885THRB 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.